Compliance to Adjuvant Chemotherapy of Patients Who Underwent Surgery for Rectal Cancer: Report from a Multi-institutional Research Network.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
27
6
2019
medline:
29
1
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
Adjuvant chemotherapy for locally advanced rectal cancer is associated with improved overall survival. However, recent evidence from randomized trials showed a compliance rate of 43 to 73%, which may affect efficacy. The aim of this multicenter retrospective analysis was to investigate the compliance rate to adjuvant treatment for patients who underwent rectal surgery for cancer. Patients who underwent surgery with curative intent for rectal cancer in six Italian colorectal centers between January 2013 and December 2017 were retrospectively reviewed. Exclusion criteria were age less than 18 years, palliative or emergency surgery, and stage IV disease. Parameters of interest were patients' characteristics, preoperative tumor stage, neo-adjuvant chemoradiation therapy, intra-operative and postoperative outcomes. Although the participating centers referred to the same treatment guidelines for treatment, the chemotherapy regiment was not standardized across the institutions. Reasons for not starting adjuvant chemotherapy when indicated, interruption, and modification of drug regimen were collected to investigate compliance. A total of 572 patients were included in the analysis. Two hundred and fifty-two (44.1%) patients received neo-adjuvant chemoradiation therapy. All patients underwent high anterior rectal resection, low anterior rectal resection, or Miles' procedure. Of 399 patients with an indication to adjuvant chemotherapy, 176 (44.1%) completed the treatment as planned. Compliance for patients who started chemotherapy was 56% (95% CI 50.4-61.6%). Sixty-six patients interrupted the treatment, 76 patients significantly reduced the drug dose, and 41 patients had to switch to other therapeutic regimens. The present multicenter investigation reports a low compliance rate to adjuvant chemotherapy after rectal resection for cancer. Multidisciplinary teams should focus on future effort to improve compliance for these patients.
Identifiants
pubmed: 31240433
doi: 10.1007/s00268-019-05060-5
pii: 10.1007/s00268-019-05060-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2544-2551Références
Cancer Treat Rev. 2018 Feb;63:156-171
pubmed: 29407455
Ann Oncol. 2014 Jul;25(7):1356-62
pubmed: 24718885
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Lancet Oncol. 2014 Feb;15(2):184-90
pubmed: 24440473
Cancer. 2017 May 1;123(9):1497-1506
pubmed: 28295220
Lancet Oncol. 2014 Oct;15(11):1245-53
pubmed: 25201358
Ann Oncol. 2015 Apr;26(4):696-701
pubmed: 25480874
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263
pubmed: 29741565
Dis Colon Rectum. 2017 Oct;60(10):1050-1056
pubmed: 28891848
Clin Oncol (R Coll Radiol). 2016 Feb;28(2):140-145
pubmed: 26698026
Lancet Oncol. 2018 Apr;19(4):562-578
pubmed: 29611518
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
World J Surg. 2016 Feb;40(2):447-55
pubmed: 26566779
Cancer. 2017 Jan 1;123(1):52-61
pubmed: 27560162
Int J Colorectal Dis. 2019 Jan;34(1):113-121
pubmed: 30368569
BMC Cancer. 2017 Mar 9;17(1):182
pubmed: 28279170